Trial Profile
Phase II, Randomized Double-blind Study of Efficacy and Safety of Two Dose Levels of LDE225 in Patients With Locally Advanced or Metastatic Basal Cell Carcinoma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 13 Dec 2023
Price :
$35
*
At a glance
- Drugs Sonidegib (Primary)
- Indications Basal cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms BOLT
- Sponsors Novartis; Novartis Pharma A.G.; Novartis Pharmaceuticals
- 24 Oct 2023 Results of an analysis assessing tumour burden reduction using photography or magnetic resonance imaging in patients with laBCC that had a time to first tumour response within 6 months of starting treatment presented at the 48th European Society for Medical Oncology Congress
- 25 Apr 2021 Results (n=79) assessing hematology changes or grade 1 hematology shifts in patients with advanced basal cell carcinoma receiving sonidegib 200 mg daily, presented at the American Academy of Dermatology Virtual Meeting Experience 2021
- 25 Apr 2021 Results assessing the analysis of antineoplastic therapies after discontinuation of sonidegib analysis of antineoplastic therapies after discontinuation of sonidegib 200 mg once daily in patients with advanced basal cell carcinoma, presented at the American Academy of Dermatology Virtual Meeting Experience 2021.